Trametinib alleviates lipopolysaccharide-induced acute kidney injury by inhibiting macrophage polarization through the PI3K/Akt pathway
Transplant Immunology · 2025
DOI: 10.1016/j.trim.2025.102183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Immunology, 2025. Verfasst von Yingqi Zeng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan 41001…. Hauptthemen laut MEDLINE: Pyridones, Pyrimidinones, Macrophages, Acute Kidney Injury. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Sepsis-induced acute kidney injury (AKI) is a severe condition characterized by dysregulation of pro- and anti-inflammatory responses. Targeting macrophage polarization between pro-inflammatory M1 and anti-inflammatory M2 cells offers a potential therapeutic approach for AKI. Trametinib (TRAM), an inhibitor of the MEK1/2 signaling pathway, was evaluated for its impact on M1/M2 polarization in AKI. METHODS: Wild-type (WT) mice were subjected to lipopolysaccharide (LPS)-induced AKI and intraperitoneally treated with dimethyl sulfoxide (DMSO) or TRAM (10 mg/kg) for three days. Renal function was assessed by measuring creatinine levels. While histopathological changes, RNA sequencing data, and serum cytokine levels were analyzed. Macrophage M1/M2 polarization in kidney tissues was examined using flow cytometry and immunohistochemistry. Murine bone marrow-derived macrophages (BMDMs) were polarized to the M1 or M2 phenotype in vivo and treated with or without TRAM (10 μM). M1/M2 polarization was analyzed via flow cytometry, and PI3K/Akt signaling was evaluated by western blotting. RESULTS: TRAM significantly improved renal function, as demonstrated by reduced serum creatinine levels (p < 0.01) and ameliorated histopathological damage (p < 0.01). Flow cytometry and immunohistochemistry revealed that TRAM markedly inhibited pro-inflammatory M1 macrophage polarization (p < 0.001). Additionally, TRAM reduced serum level of IFN-γ (p < 0.01) and IL-17 (p < 0.001). In vitro, TRAM suppressed M1 polarization (p < 0.05) by inhibiting the PI3K/Akt signaling pathway. CONCLUSION: TRAM mitigated LPS-induced AKI by suppressing M1 macrophage polarization via the PI3K/Akt pathway, highlighting its therapeutic potential for AKI and other inflammatory kidney diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Kidney Transplantation, Center of Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China; Clinical Research Center for Organ Transplantation in Hunan…
- Academic Affairs Department, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Zitieren
APA
Zeng, Y., Yuan, W., Feng, C., Peng, L., Xie, X., Peng, F., Li, T., Lin, M., Zhang, H., & Dai, H. (2025). Trametinib alleviates lipopolysaccharide-induced acute kidney injury by inhibiting macrophage polarization through the PI3K/Akt pathway. Transplant Immunology. https://doi.org/10.1016/j.trim.2025.102183
Vancouver
Zeng Y, Yuan W, Feng C, Peng L, Xie X, Peng F, et al. Trametinib alleviates lipopolysaccharide-induced acute kidney injury by inhibiting macrophage polarization through the PI3K/Akt pathway. Transplant Immunology. 2025. doi:10.1016/j.trim.2025.102183
BibTeX
@article{Zeng2025,
author = {Zeng, Yingqi and Yuan, Wenjia and Feng, Chen and Peng, Longkai and Xie, Xubiao and Peng, Fenghua and Li, Tengfang and Lin, Minjie and Zhang, Hedong and Dai, Helong},
title = {Trametinib alleviates lipopolysaccharide-induced acute kidney injury by inhibiting macrophage polarization through the PI3K/Akt pathway},
journal = {Transplant Immunology},
year = {2025},
doi = {10.1016/j.trim.2025.102183}
}
EUVIMED